JOINN Laboratories (China) Co., Ltd. Class H (HK:6127) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
JOINN Laboratories has entered into a 2025 service agreement with Staidson, promising to deliver a comprehensive suite of pharmaceutical research and development services. This partnership, effective from January 2025, highlights a strategic collaboration in non-clinical and clinical trial stages. The agreement is categorized as a continuing connected transaction under the Hong Kong Stock Exchange rules.
For further insights into HK:6127 stock, check out TipRanks’ Stock Analysis page.